The trading price of Viking Therapeutics, Inc. (NASDAQ:VKTX) closed higher on Tuesday, Jan 12, closing at $6.71, 1.79% higher than its previous close.
Traders who pay close attention to intraday price movement should know that it fluctuated between $6.73 and $7.06. The company’s P/E ratio in the trailing 12-month period was 0, while its 5Y monthly beta was 1.84. In examining the 52-week price action we see that the stock hit a 52-week high of $8.36 and a 52-week low of $3.26. Over the past month, the stock has gained 11.42% in value.
Viking Therapeutics, Inc., whose market valuation is $475.03 Million at the time of this writing, is expected to release its quarterly earnings report in Feb 2021. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by -$0.15 per share this quarter, however they have predicted annual earnings per share of -$0.55 for 2021 and -$0.78 for 2022. It means analysts are expecting annual earnings per share growth of 0.53% this year and 0.42% next year.
On the technical side, indicators suggest VKTX has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 50% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned VKTX a recommendation rating is 14. Out of them, no one rate it a Hold, while 14 recommend Buy, whereas none assign an Outperform rating. None analyst(s) have tagged Viking Therapeutics, Inc. (VKTX) as Underperform, while not any of them advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 0, which symbolizes a positive outlook. A quick review shows that VKTX’s price is currently 9.69% off the SMA20 and 10.45% off the SMA50. The RSI metric on the 14-day chart is currently showing 64.3, and weekly volatility stands at 5.18%. When measured over the past 30 days, the indicator reaches 5%. Viking Therapeutics, Inc. (NASDAQ:VKTX)’s beta value is currently sitting at 1.84, while the Average True Range indicator is currently displaying 0.31. With analysts defining $12-$40 as the low and high price targets, we arrive at a consensus price target of $19.54 for the trailing 12-month period. The current price is about 75.7% off the estimated low and 485.65% off the forecast high, based on this estimate. Investors will be thrilled if VKTX’s share price rises to $18, which is the median consensus price. At that level, VKTX’s share price would be +163.54% above current price.
To see how Viking Therapeutics, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: VKTX stock’s performance was +1.79% in the latest trading, and -6.44% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +0.71% on the day and positioned -1.09% lower than it was a year ago. Another comparable company Amgen Inc (AMGN) saw its stock close -0.41% lower in the most recent trading session but was down -0.14% in a year. Furthermore, Gilead Sciences Inc (GILD) showed an increase of 1.79% on the day while its price kept declining at -6.44% over the past year. Viking Therapeutics, Inc. has a P/E ratio of 0, compared to Bristol-Myers Squibb Company’s 0 and Amgen Inc’s 19.08. Also in last trading session, the S&P 500 Index has surged 0.04%, while the Dow Jones Industrial also saw a positive session, up +0.19% on the day.
An evaluation of the daily trading volume of Viking Therapeutics, Inc. (NASDAQ:VKTX) indicates that the 3-month average is 1.22 Million. However, this figure has increased over the past 10 days to an average of 1.39 Million.
Currently, records show that 72.95 Million of the company’s shares remain outstanding. According to Thomson Reuters data, insiders hold 10.51% of outstanding shares, whereas institutions hold 56.71%. The stats also highlight that short interest as of December 14, 2020, stood at 8.81 Million shares, resulting in a short ratio of 7.1 at that time. From this, we can conclude that short interest is 12.08% of the company’s total outstanding shares. It is noteworthy that short shares in December were down slightly from the previous month’s figure, which was 10.71 Million. However, since the stock’s price has seen +21.31% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.